ROXI-ATLASNCT07175428
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 25 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 87 → 91 locations
- Minor Study sites: 87 to 89
- Minor Trial sites expanded: 84 → 87 locations
- Minor Trial sites expanded: 81 → 84 locations
- Notable Eligibility criteria expanded, about 12 words
- Trial sites expanded: 77 → 81 locations
- Minor Trial sites expanded: 74 → 77 locationsv20
- Minor Trial sites expanded: 70 → 74 locationsv19
- Minor Trial sites expanded: 59 → 70 locationsv18
- Minor Trial sites expanded: 48 → 59 locationsv17
- Minor Trial sites expanded: 45 → 48 locationsv16
- Minor Study sites revised (45)v15
- Notable Eligibility criteria shortened, about 7 words
- Trial sites expanded: 42 → 45 locations
- Minor Study sites: 41 to 42v13
- Minor Trial sites expanded: 37 → 41 locationsv12
- Minor Study sites: 34 to 37v11
- Minor Study sites: 30 to 34v10
- Minor Study sites: 25 to 30v9
- Minor Study sites: 21 to 25v8
- Minor Study sites: 20 to 21v7
- Minor Study sites: 15 to 20v6
- Minor Study sites: 13 to 15v5
- Minor Study sites: 5 to 13v4
- Minor Study sites: 2 to 5v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Study sites: 0 to 2
- Primary completion date: Apr 26, 2027 to Feb 9, 2027
- Study completion date: Apr 26, 2027 to Apr 21, 2027
- Start date changed from estimate of Oct 21, 2025 to Oct 20, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of any bleeding
Timeframe: 12 weeks
Secondary (18)
Incidence of the composite of ISTH major bleeding or ISTH CRNM bleeding
Incidence of ISTH major bleeding
Incidence of ISTH CRNM bleeding
Incidence of minor bleeding
Number of ISTH major bleeding events
Show 13 moreShow less
Number of ISTH CRNM bleeding events
Number of minor bleeding events
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Incidence of the composite of stroke or systemic embolism
Incidence of Antidrug Antibodies (ADA) to REGN7508
Magnitude of ADA to REGN7508
Incidence of ADA to REGN9933
Magnitude of ADA to REGN9933
Concentrations of REGN7508
Concentrations of REGN9933
Change from baseline in activated Partial Thromboplastin Time (aPTT)
Change from baseline in Prothrombin Time (PT)
Arms and interventions
REGN7508Experimental
REGN9933Experimental
ApixabanActive comparator
Drugs: REGN7508, REGN9933, Apixaban
Sites
91 sites in 4 countries
United States 43, Brazil 24, Canada 16, Argentina 8